Companies press releases
Nov 12, 2020, 07:30 ET CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive […]
– $82.9 Million in Cash and Cash Equivalents at June 30, 2020 – Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi® in July 2020 Resulted in Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 – Phase 2 Study Data of PL9643 for the Treatment of Dry Eye Disease
Sep 24, 2020, 16:00 ET CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September 28, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by
Sep 10, 2020, 17:47 ET CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced today that it will be presenting at the H.C. Wainwright & Co., 22nd Annual
Aug 13, 2020, 16:12 ET CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity’s 40th Annual Growth Conference in a Fireside Chat today
Palatin Technologies Participates In Canaccord Genuity’s 40th Annual Growth Conference Read More »
Data Anticipated Q4 2020 Aug 05, 2020, 07:30 ET CRANBURY, N.J., Aug. 5, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced completion of enrollment of its Phase 2 study with
Palatin Regains All Rights Company to Receive $16.3 Million from AMAG Teleconference and Webcast to be held on July 27, 2020 Jul 27, 2020, 07:00 ET CRANBURY, N.J., July 27, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin
Data Anticipated Q4 2020 Jul 08, 2020, 07:30 ET CRANBURY, N.J., July 8, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced reinitiation of enrollment of its Phase 2 study with
– Limited to Proposal 4, Amendment to Certificate of Incorporation to Increase Authorized Common Stock – Proposals 1, 2, 3 and 5 were approved at the Annual Meeting – Scheduled to Reconvene July 23, 2020, 9:00 am Eastern Daylight Time Jun 29, 2020, 07:30 ET CRANBURY, N.J., June 29, 2020 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”)
Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders Read More »
– Engages with Scientific, Governmental and Regulatory Agencies – Targeting Q4 2020 Initiation of an Adaptive Phase 2 Trial Jun 23, 2020, 07:30 ET CRANBURY, N.J., June 23, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide
